www.bewet.fora.pl

kah6omi4ny

Biosimilars technology market
Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry
Each section will provide market data [link widoczny dla zalogowanych], market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.
For more information please contact :
/reports/Biosimilars-2009-2014--29843.html
/
From:Aarkstore Enterprise
Contact: Neel
Email: [link widoczny dla zalogowanych]
URL: />
Biosimilars product market
Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

Biosimilars service market
Contract research and manufacturing services [link widoczny dla zalogowanych], clinical trials services
ort Description
The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins [link widoczny dla zalogowanych], and others.
The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilarss market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.
Asias early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddys Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.
Scope of the Report
This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.
Biosimilars applications market
Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases

相关的主题文章：

Puma First Round Awesome How To Video Puma Espera

Puma Espera II Aarkstore Enterprise Puma First Rou

Puma Complete Vectana 51 Houaokesi Puma First Rou